Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03621020 · ClinicalTrials.gov registry record
Clinical Performance Evaluation of T-TAS 01 PL Chip
A clinical trial, sponsored by Hikari Dx.
- Completed
- Registry status
- 307
- Enrollment target
NCT03621020: Completed study, sponsored by Hikari Dx.
NCT03621020 is a clinical trial that has completed, run by Hikari Dx. The registered enrollment target is 307 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03621020 has completed, sponsored by Hikari Dx.
- COMPLETED
- Registry status
- 307 participants
- Enrollment target
Study Summary
This study will measure primary hemostatic ability using the T-TAS 01 System with PL chip, with a comparison to clinical truth.
Primary Outcome
Sensitivity and specificity of the T-TAS 01 PL chip assay against clinical truth
Interventions
- DIAGNOSTIC_TEST T-TAS 01 PL Chip
- DIAGNOSTIC_TEST PFA-100 Col/Epi and Col/ADP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2020-02-14 |
What the finished NCT03621020 record still lists
NCT03621020 is an observational study that tracks outcomes without assigning an intervention. The registered 307 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which T-TAS 01 PL Chip is the first listed.
NCT03621020 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03621020 about?
NCT03621020 is a clinical study titled "Clinical Performance Evaluation of T-TAS 01 PL Chip". This study will measure primary hemostatic ability using the T-TAS 01 System with PL chip, with a comparison to clinical truth.
What is the current status of trial NCT03621020?
This trial is currently completed. The enrollment target is 307 participants. The study started on 2018-09-01. Estimated completion is 2020-02-14.
What interventions are being tested in trial NCT03621020?
The interventions under investigation include: T-TAS 01 PL Chip (DIAGNOSTIC_TEST), PFA-100 Col/Epi and Col/ADP (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03621020?
This trial is sponsored by Hikari Dx, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05433142 · 307 participants · Phase 1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI